Jayaprakash K Nair

This inventor holds 43 USPTO granted patents and 40 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Drug Delivery Technologies. Top assignees: Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Takeda Pharmaceutical Company Limited. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jayaprakash K Nair. Retrieved from https://idiyas.com/inventor/jayaprakash-k-nair

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 40)

% Patents Active = 95.3

CIPO Patents = 1 (Patent Applications = 17)

EPO Patents = 2 (Patent Applications = 26)

Average Co-Inventor Count = 6.2

ph-index = 10

Forward Citations = 352(Granted Patents)

Company Filing History:

36 out of 466

Alnylam Pharmaceuticals, Inc.

patents

7 out of 57

Arbutus Biopharma Corporation

patents

1 out of 1,226

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Biodegradable Lipids

Oligonucleotide Conjugates

Modified RNA Agents

Drug Delivery

Carbohydrate Conjugates

Therapeutics

Endosomal Linkers

PEGylated Lipids

Multi-Targeted Conjugates

Chirally-Enriched RNA

Active Agent Delivery

Lipid Formulations

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735702 - ENDOSOMAL CLEAVABLE LINKERS (2026-09-15),

2. 12653893 - Carbohydrate conjugated RNA agents and process for their preparation (2026-06-16),

3. 12397013 - Extrahepatic delivery (2025-08-26),

4. 12364762 - Biodegradable lipids for the delivery of active agents (2025-07-22),

5. 12350338 - Biodegradable lipids for the delivery of active agents (2025-07-08),

6. 12343398 - Biodegradable lipids for the delivery of active agents (2025-07-01),

7. 12275938 - Modified RNA agents with reduced off-target effect (2025-04-14),

8. 12247203 - Modified RNA agents with reduced off-target effect (2025-03-11),

9. 12239709 - Biodegradable lipids for the delivery of active agents (2025-03-04),

10. 12221607 - Multi-targeted single entity conjugates (2025-02-11),

11. 12173288 - Oligonucleotide-ligand conjugates and process for their preparation (2024-12-24),

12. 12059468 - Carbohydrate conjugates as delivery agents for oligonucleotides (2024-08-13),

13. 12005074 - Extrahepatic delivery (2024-06-11),

14. 11944687 - Carbohydrate conjugate RNA agents and process for their preparation (2024-04-02),

15. 11725207 - Serpina1 iRNA compositions and methods of use thereof (2023-08-15),

Title: Innovator Spotlight - Jayaprakash K Nair

Introduction:

Jayaprakash K Nair is a prolific inventor based in Cambridge, MA, with an impressive portfolio of 32 patents to his name. His groundbreaking work in the field of oligonucleotide delivery has revolutionized the way gene silencing is approached in the medical field.

Latest Patents:

Among his latest patents is the innovative "Carbohydrate conjugates as delivery agents for oligonucleotides," which introduces a novel phosphorothioate-modified oligonucleotide structure to enhance delivery efficiency. Additionally, Nair's "Extrahepatic delivery" patent unveils a method for gene silencing by administering lipophilic moieties-conjugated double-stranded iRNAs, opening up new possibilities for therapeutic interventions.

Career Highlights:

Nair has made significant contributions to leading biopharmaceutical companies such as Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma Corporation. His expertise in developing cutting-edge technologies for drug delivery systems has positioned him as a key figure in the industry.

Collaborations:

Throughout his career, Nair has collaborated with esteemed professionals in the field, including Muthiah Manoharan and Kallanthottathil G Rajeev. These collaborations have led to innovative solutions and advancements in the realm of genetic therapeutics.

Conclusion:

Jayaprakash K Nair's dedication to research and innovation has solidified his reputation as a trailblazer in the field of gene silencing and drug delivery. His patented inventions continue to shape the landscape of modern medicine, offering hope for improved treatments and outcomes in the future.

Profile summary based on public USPTO records.